176 related articles for article (PubMed ID: 33115981)
21. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.
Sutherland KD; Song JY; Kwon MC; Proost N; Zevenhoven J; Berns A
Proc Natl Acad Sci U S A; 2014 Apr; 111(13):4952-7. PubMed ID: 24586047
[TBL] [Abstract][Full Text] [Related]
22. K-ras p21 expression and activity in lung and lung tumors.
Ramakrishna G; Sithanandam G; Cheng RY; Fornwald LW; Smith GT; Diwan BA; Anderson LM
Exp Lung Res; 2000 Dec; 26(8):659-71. PubMed ID: 11195463
[TBL] [Abstract][Full Text] [Related]
23. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathogenesis of transplacentally induced mouse lung tumors.
Miller MS; Leone-Kabler S; Rollins LA; Wessner LL; Fan M; Schaeffer DO; McEntee MF; O'Sullivan MG
Exp Lung Res; 1998; 24(4):557-77. PubMed ID: 9659583
[TBL] [Abstract][Full Text] [Related]
25. Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivo.
Talluri S; Francis SM; Dick FA
PLoS One; 2013; 8(8):e72236. PubMed ID: 23936539
[TBL] [Abstract][Full Text] [Related]
26. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic downregulation of RUNX3 by DNA methylation induces docetaxel chemoresistance in human lung adenocarcinoma cells by activation of the AKT pathway.
Zheng Y; Wang R; Song HZ; Pan BZ; Zhang YW; Chen LB
Int J Biochem Cell Biol; 2013 Nov; 45(11):2369-78. PubMed ID: 23892093
[TBL] [Abstract][Full Text] [Related]
28. Association of p53, K-ras and proliferating cell nuclear antigen with rat lung lesions following exposure to simulated nuclear fuel particles.
Kosma VM; Lang PS; Servomaa MK; Leszczynski D; Rytömaa TJ
Cancer Detect Prev; 1999; 23(3):194-203. PubMed ID: 10336998
[TBL] [Abstract][Full Text] [Related]
29. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
[TBL] [Abstract][Full Text] [Related]
30. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.
Mallakin A; Sugiyama T; Taneja P; Matise LA; Frazier DP; Choudhary M; Hawkins GA; D'Agostino RB; Willingham MC; Inoue K
Cancer Cell; 2007 Oct; 12(4):381-94. PubMed ID: 17936562
[TBL] [Abstract][Full Text] [Related]
31. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
32. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis.
Bauer AK; Umer M; Richardson VL; Cumpian AM; Harder AQ; Khosravi N; Azzegagh Z; Hara NM; Ehre C; Mohebnasab M; Caetano MS; Merrick DT; van Bokhoven A; Wistuba II; Kadara H; Dickey BF; Velmurugan K; Mann PR; Lu X; Barón AE; Evans CM; Moghaddam SJ
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089720
[TBL] [Abstract][Full Text] [Related]
33. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.
Wang Y; Zhang Z; Lubet RA; You M
Oncogene; 2006 Feb; 25(8):1277-80. PubMed ID: 16247444
[TBL] [Abstract][Full Text] [Related]
34. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
35. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
Vatan O; Bilaloglu R; Tunca B; Cecener G; Gebitekin C; Egeli U; Yakut T; Urer N
Tumori; 2007; 93(5):473-7. PubMed ID: 18038880
[TBL] [Abstract][Full Text] [Related]
36. Osteopontin drives KRAS-mutant lung adenocarcinoma.
Giopanou I; Kanellakis NI; Giannou AD; Lilis I; Marazioti A; Spella M; Papaleonidopoulos V; Simoes DCM; Zazara DE; Agalioti T; Moschos C; Magkouta S; Kalomenidis I; Panoutsakopoulou V; Lamort AS; Stathopoulos GT; Psallidas I
Carcinogenesis; 2020 Aug; 41(8):1134-1144. PubMed ID: 31740923
[TBL] [Abstract][Full Text] [Related]
37. Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening.
Lee SJ; Jung YS; Lee SH; Chung HY; Park BJ
Int J Oncol; 2009 Jun; 34(6):1637-43. PubMed ID: 19424582
[TBL] [Abstract][Full Text] [Related]
38. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
[TBL] [Abstract][Full Text] [Related]
39. RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis.
Schmidt ML; Hobbing KR; Donninger H; Clark GJ
Cancer Res; 2018 May; 78(10):2614-2623. PubMed ID: 29735543
[TBL] [Abstract][Full Text] [Related]
40. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]